Baxter International Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Baxter International, Inc. (BAX)

If you purchased or acquired Baxter International securities between February 23, 2022 and July 30, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About Baxter International

Baxter International, founded in 1931 and headquartered in Deerfield, Illinois, operates in the medical devices industry. The company develops, manufactures, and markets a range of healthcare products used in hospitals and other healthcare facilities.

One of Baxter’s core business segments is Medical Products & Therapies, which includes the production of sterile IV solutions, infusion systems, and related therapies.

The Allegations

The complaint alleges that Baxter and certain executives misled investors about the safety and commercial success of the Novum IQ Large Volume Pump, an infusion device used to deliver fluids and medications. The class action complaint alleges that throughout the class period, Baxter described Novum as a best in class platform with advanced safety features and told investors the United States launch was going well.

According to the filing, the device had systemic problems in the field. Reports described underinfusion, overinfusion, and complete non-delivery of fluids. The complaint alleges Baxter received many adverse event reports, including seventy nine serious injuries and two patient deaths, while continuing to promote the product and its rollout.

Concerns became public in April 2025 when a whistleblower report from a St. Louis hospital system raised safety issues. Baxter then sent customer letters on April 24, 2025 and July 14, 2025 discussing risks of underinfusion and overinfusion. According to the complaint, the FDA classified the issues as a Class I recall. On July 31, 2025, Baxter announced a voluntary pause of all new Novum sales and installations and said it could not give a timing for resuming shipments. After that disclosure, Baxter’s stock price fell 22.4%, from $28.05 to $21.76 on July 31, 2025, causing investors significant harm.

The class period for this lawsuit is from February 23, 2022 to July 30, 2025. Investors who purchased Baxter securities during this time may have been harmed by the alleged misrepresentations and omissions.

Important Dates

• Class period: February 23, 2022 to July 30, 2025
• Complaint filed: October 16, 2025
• Lead plaintiff deadline: December 15, 2025

Your Rights and Next Steps

If you purchased Baxter International securities during the class period, you may have the right to participate in this class action lawsuit. As an investor, you can seek to recover losses that resulted from the alleged securities fraud.

Here’s what you need to know:

• You do not need to have sold your shares to be eligible.
• If you suffered financial losses due to the drop in Baxter’s stock price after the July 31, 2025 disclosure, you may qualify to join the lawsuit.
• The lead plaintiff (sometimes called the class representative) is the investor chosen to represent the interests of all class members. The deadline to seek appointment as lead plaintiff is December 15, 2025.
• Even if you do not become the lead plaintiff, you may still be eligible to receive a recovery if the lawsuit is successful or settles.

Lawyers are ready to help guide you through the process and answer any questions about your eligibility or the claims process.

You May Be Entitled to Compensation

If you invested in Baxter International securities during the Class Period and experienced losses, you may be entitled to compensation. Lawyers are ready to help investors understand their options and pursue claims for recovery.

Complete the form below to join the lawsuit investigation and protect your rights.